Exact Sciences reports record Q4 and full-year 2025 results

The cancer screening and diagnostics company saw strong growth across its portfolio.

Published on Feb. 14, 2026

Got story updates? Submit your updates here. ›

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that the company generated record revenue and earnings in the fourth quarter and full year of 2025. The company cited strong performance across its portfolio of cancer screening and diagnostic products.

Why it matters

Exact Sciences is a major player in the growing cancer diagnostics market, which is being driven by increased demand for early detection and screening tools. The company's strong financial results indicate that its products are resonating with patients and healthcare providers, positioning it for continued growth in the years ahead.

The details

Exact Sciences reported that it generated record revenue and earnings in Q4 2025 and for the full year. The company attributed the strong performance to growing adoption of its suite of cancer screening and diagnostic tests, including its flagship Cologuard colorectal cancer screening test.

  • Exact Sciences announced its Q4 2025 and full-year 2025 results on February 14, 2026.

The players

Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, headquartered in Madison, Wisconsin.

Got photos? Submit your photos here. ›

The takeaway

Exact Sciences' strong financial performance in 2025 underscores the growing demand for its cancer screening and diagnostic products, positioning the company for continued growth in the years ahead as the cancer diagnostics market expands.